



Quest Diagnostics Stockholders Elect John B. Ziegler to Board of Directors

May 9, 2000

NEW YORK, N.Y., May 9, 2000 —

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that John B. Ziegler was elected to serve a three-year term on its board of directors. The election was held at the company's annual meeting of shareholders today.

Mr. Ziegler, 53, is President, Worldwide Consumer Healthcare, of SmithKline Beecham. Mr. Ziegler joined SmithKline Beecham in 1991 as the head of SB Consumer Healthcare-North American Division. He became Executive Vice President of SmithKline Beecham in 1996 and assumed his current responsibilities in 1998. Mr. Ziegler succeeds John O. Parker as a director on the Quest Diagnostics board, pursuant to the company's Stockholders Agreement with SmithKline Beecham.

In addition, shareholders reelected the two other existing members of the Quest Diagnostics board whose terms were expiring and were nominated for new three-year terms: Kenneth W. Freeman, Chairman of the Board and Chief Executive Officer of Quest Diagnostics, and Gail R. Wilensky, the John M. Olin Senior Fellow at Project HOPE, an international non-profit health foundation.

Quest Diagnostics is the nation's leading provider of diagnostic testing, information and services with annualized revenues of more than \$3 billion. The testing performed on human specimens helps doctors diagnose, treat and monitor disease; enables employers to detect workplace drug abuse; and supports pharmaceutical and biotechnology companies in clinical trials of new therapeutics worldwide. Quest Informatics analyzes laboratory and other medical data to help health care providers improve the care of patients. Additional company information can be found on the Internet at: www.questdiagnostics.com.

###